

## COMPLETION OF CAPITAL RAISING

**Perth, Australia, 11 July 2017:** Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1 LSL** or the **Company**) is pleased to announce that further to the ASX announcement on 5 April 2017, it has today issued a total of 137,165,811 shares at an issue price of A\$0.008 raising approximately A\$1.097 million (before costs) (“**Placement**”).

BARD1 provides the following information pursuant to Listing Rule 3.10.5A:

- 55,199,658 shares have been issued pursuant to BARD1’s Listing Rule 7.1A capacity (“7.1A Placement”). The shares issued pursuant to the 7.1A Placement represent 8.0% of the post Placement capital in the Company. Pre- Placement shareholders overall interests will therefore be diluted by 8.0% following the 7.1A Placement (however some existing shareholders have participated in the Placement so their particular interests may have increased or been diluted to a lesser extent).
- The remainder of 81,966,153 shares in the Placement have been issued pursuant to BARD1’s Listing Rule 7.1 capacity (“7.1 Placement”). These shares represent 11.9% of the post Placement capital in the Company. Pre- Placement shareholders overall interests will therefore be diluted by 11.9% following the 7.1 Placement (however some existing shareholders have participated in the Placement so their particular interests may have increased or been diluted to a lesser extent).

The following table provides details of participation by existing shareholders and new investors who participated in the component of the Placement issued under the Company’s ASX Listing Rule 7.1A capacity:

	%
Shares held by pre-Placement shareholders who did not participate in the ASX Listing Rule 7.1A component of the Placement	89.88
Shares held by pre-Placement shareholders who did participate in the ASX Listing Rule 7.1A component of the Placement	0
Shares held by new shareholders who participated in the ASX Listing Rule 7.1A component of the Placement	8
Shares held by new shareholders who participated in the ASX Listing Rule 7.1 component of the Placement but did not participate in the ASX Listing Rule 7.1A component of the Placement	2.12

BARD1 issued the Shares by way of the 7.1A Placement and not by way of a pro-rata offer as it considered that this was the most appropriate way of raising funds in the circumstances, providing certainty for the Company going forward.

The Placement was not underwritten. The Company will pay a 6% capital raising fee on the funds raised under the Placement. BARD1 has also incurred miscellaneous expenses including legal, listing and other advisory fees in connection with the Placement.

An Appendix 3B applying for quotation of the shares has been lodged together with a cleansing notice in respect of the Placement shares pursuant to section 708A(5)(e) of the *Corporations Act 2001* (Cth) (Corporations Act).

As advised in the 5 July 2017 announcement the Company is conducting a Share Purchase Plan for eligible shareholders to raise up to a further \$1 million (**SPP**).

The SPP will enable existing eligible shareholders to participate in the capital raising by applying for up to \$15,000 worth of shares at the same issue price as the Placement and without incurring any brokerage fees or other transaction costs. The issue price of \$0.008 per share represents a 19.1% discount to the 5 day VWAP of \$0.009894 per share up to 30 June 2017, being the last trading day prior to the Company's announcement of the SPP. The SPP Offer document was lodged on ASX on 11 July 2017.

Funds raised from the Placement and SPP will be used to fund ongoing research and development programs, commercial initiatives and for general working capital purposes.

- ENDS -

**FOR MORE INFORMATION PLEASE CONTACT:**

**Peter Gunzburg**  
Chairman  
E [peter@bard1.com](mailto:peter@bard1.com)

**Dr Leearne Hinch**  
CEO  
E [leearne@bard1.com](mailto:leearne@bard1.com)  
M +61 400 414 416